AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35430924 — intervention group
Group type: COMPARATOR
Intervention: No external application (Control)
Number of subjects: 20
Study 33487470 — intervention group
Group type: EXPERIMENTAL
Intervention: sIPV (inactivated poliomyelitis vaccine made from Sabin strains)
Number of subjects: 1200
Study 32726529 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV fusion (F) protein nanoparticle vaccine
Number of subjects: 4636
Study 32726529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4636
Study 35081076 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone therapy in immune-adaptive prevalent (IA-P) patients
Number of subjects: 0
Study 35081076 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone therapy in immune-innate prevalent (IN-P) patients
Number of subjects: 0
Study 35081076 — intervention group
Group type: COMPARATOR
Intervention: Placebo in IA-P patients
Number of subjects: 0
Study 35081076 — intervention group
Group type: COMPARATOR
Intervention: Placebo in IN-P patients
Number of subjects: 0
Study 33675704 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfragmented adipose tissue injection using Lipogems technology
Number of subjects: 40
Study 33675704 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with hyaluronic acid injection
Number of subjects: 40
Study 36326712 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain wheat-fiber diet
Number of subjects: 169
Study 36326712 — intervention group
Group type: COMPARATOR
Intervention: Low-GI diet
Number of subjects: 169
Study 34936957 — intervention group
Group type: EXPERIMENTAL
Intervention: Early weaning (EW)
Number of subjects: 16
Study 34831609 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactical Games Approach (TGA)
Number of subjects: 49
Study 34831609 — intervention group
Group type: COMPARATOR
Intervention: Direct Instruction (DI)
Number of subjects: 49
Study 34831609 — intervention group
Group type: COMPARATOR
Intervention: Service Teacher’s Basketball Unit (STBU)
Number of subjects: 49
Study 32567439 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 45
Study 32567439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 35311438 — intervention group
Group type: EXPERIMENTAL
Intervention: OPTICARE XL CR
Number of subjects: 201
Study 35311438 — intervention group
Group type: COMPARATOR
Intervention: Standard CR
Number of subjects: 201
Study 35311438 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 201
Study 33647171 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekend admission
Number of subjects: 753
Study 33647171 — intervention group
Group type: EXPERIMENTAL
Intervention: Change of treating team
Number of subjects: 753
Study 32522904 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5×10^7 cells of a human Muse cell‐based product, CL2020
Number of subjects: 3
Study 34626059 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition (biceps curls)
Number of subjects: 27
Study 34626059 — intervention group
Group type: COMPARATOR
Intervention: Control condition (non-exercise)
Number of subjects: 27
Study 34672445 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Platelet Volume (MPV) measurement in patients with proven VTE (316 patients)
Number of subjects: 440
Study 34672445 — intervention group
Group type: COMPARATOR
Intervention: Mean Platelet Volume (MPV) measurement in control group (124 patients)
Number of subjects: 440
Study 32241371 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga‐CaRe program (n = 1,970)
Number of subjects: 3959
Study 32241371 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard care (n = 1,989)
Number of subjects: 3959
Study 34447851 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (2.5 mg/100 ml normal saline)
Number of subjects: 200
Study 34447851 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (10 mg/100 ml normal saline)
Number of subjects: 200
Study 35585105 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Hz tACS
Number of subjects: 0
Study 35585105 — intervention group
Group type: COMPARATOR
Intervention: 40-Hz tACS (control frequency)
Number of subjects: 0
Study 35585105 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 33904601 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel containing propolis extract, nanovitamin C and nanovitamin E, used as toothpaste three times/day for 1 month.
Number of subjects: 46
Study 34654966 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative CT-based radiomic nomogram combining clinical and radiomic signatures
Number of subjects: 373
Study 34654966 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radiomic signature from nodular and perinodular areas
Number of subjects: 373
Study 34654966 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomic nomogram
Number of subjects: 373
Study 32661013 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular point-of-care testing (POCT) for influenza
Number of subjects: 312
Study 34561695 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobicistat (150 mg q24h orally)
Number of subjects: 15
Study 34561695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 34561695 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobicistat with GHB (25 mg/kg)
Number of subjects: 15
Study 34561695 — intervention group
Group type: COMPARATOR
Intervention: GHB alone (25 mg/kg)
Number of subjects: 15
Study 33672449 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidirectional running sprint training intervention (12 sessions over 4 weeks)
Number of subjects: 31
Study 33672449 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 31
Study 36351185 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga practice for 60 minutes per day including Jala Neti thrice a week, Yoga Nidra once a week for 30 days, plus three days for an orientation program.
Number of subjects: 24
Study 36351185 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control group).
Number of subjects: 24
Study 36351185 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga practice (intervention group).
Number of subjects: 24
Study 33228787 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site testing and antiviral treatment for influenza (baloxavir or oseltamivir depending on age and comorbidities)
Number of subjects: 3200
Study 33228787 — intervention group
Group type: COMPARATOR
Intervention: Control arm with routine surveillance for ARI
Number of subjects: 3200
Study 33186704 — intervention group
Group type: EXPERIMENTAL
Intervention: leronlimab
Number of subjects: 10
Study 34353069 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetic energy progressive exercise (PEKE)
Number of subjects: 98
Study 34353069 — intervention group
Group type: COMPARATOR
Intervention: Routine intervention (RI)
Number of subjects: 98
Study 33314786 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing blended with brief Cognitive Behavioural Therapy (MI‐CBT)
Number of subjects: 234
Study 33314786 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC) sessions
Number of subjects: 234
Study 33314786 — intervention group
Group type: EXPERIMENTAL
Intervention: MI‐CBT
Number of subjects: 234
Study 33314786 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MI‐CBT and EUC
Number of subjects: 234
Study 35152036 — intervention group
Group type: EXPERIMENTAL
Intervention: TranS‐C and usual care
Number of subjects: 121
Study 35152036 — intervention group
Group type: COMPARATOR
Intervention: Usual care followed by delayed TranS‐C
Number of subjects: 121
Study 33797688 — intervention group
Group type: EXPERIMENTAL
Intervention: MA17 (breast cancer)
Number of subjects: 2752
Study 33797688 — intervention group
Group type: EXPERIMENTAL
Intervention: PR7 (prostate cancer)
Number of subjects: 2752
Study 33797688 — intervention group
Group type: EXPERIMENTAL
Intervention: LY12 (non-Hodgkin’s lymphoma)
Number of subjects: 2752
Study 32356684 — intervention group
Group type: EXPERIMENTAL
Intervention: Shunt use (31.6% of patients, 25 patients)
Number of subjects: 79
Study 32356684 — intervention group
Group type: COMPARATOR
Intervention: Non-shunt use
Number of subjects: 79
Study 32356684 — intervention group
Group type: EXPERIMENTAL
Intervention: Shunt use
Number of subjects: 79
Study 33684650 — intervention group
Group type: EXPERIMENTAL
Intervention: AA-reduced diet (20% lower levels of lysine, total sulfur AA, and threonine)
Number of subjects: 1280
Study 33684650 — intervention group
Group type: COMPARATOR
Intervention: Control diet (highest digestible AA levels)
Number of subjects: 1280
Study 35086501 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered matching guidelines (PCPM) applied during referral decision-making from inpatient qualified withdrawal program to aftercare.
Number of subjects: 250
Study 35086501 — intervention group
Group type: EXPERIMENTAL
Intervention: PCPM implementation process evaluated by clinic staff.
Number of subjects: 250
Study 35086501 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of foregoing substance abuse treatments as a predictor for aftercare matching.
Number of subjects: 250
Study 33719709 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 20 mg
Number of subjects: 36
Study 33719709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 32302790 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal therapy (FT)
Number of subjects: 2450
Study 32302790 — intervention group
Group type: COMPARATOR
Intervention: Radical treatment
Number of subjects: 2450
Study 32302790 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal therapy (FT) with neoadjuvant agents
Number of subjects: 2450
Study 32302790 — intervention group
Group type: COMPARATOR
Intervention: Focal therapy (FT) alone
Number of subjects: 2450
Study 34139896 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie deprivation
Number of subjects: 0
Study 34139896 — intervention group
Group type: COMPARATOR
Intervention: Control (normal eating)
Number of subjects: 0
Study 33591230 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic liability to MDD
Number of subjects: 660937
Study 33591230 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic liability to MS
Number of subjects: 660937
Study 33591230 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic predisposition toward higher BMI
Number of subjects: 660937
Study 32639376 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-observation method with direct instructions (SO-DI)
Number of subjects: 48
Study 32639376 — intervention group
Group type: COMPARATOR
Intervention: Self-observation alone (SO)
Number of subjects: 48
Study 32639376 — intervention group
Group type: COMPARATOR
Intervention: Direct instruction (DI)
Number of subjects: 48
Study 32639376 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 34384043 — intervention group
Group type: EXPERIMENTAL
Intervention: Clay soils
Number of subjects: 50
Study 34384043 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandy soils
Number of subjects: 50
Study 34384043 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban soils
Number of subjects: 50
Study 32445618 — intervention group
Group type: EXPERIMENTAL
Intervention: ROI‐w radiomics model
Number of subjects: 137
Study 32445618 — intervention group
Group type: EXPERIMENTAL
Intervention: ROI‐r radiomics model
Number of subjects: 137
Study 32445618 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model (ROI‐w features, albumin, periportal edema)
Number of subjects: 137
Study 32445618 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ROI‐w and ROI‐r models
Number of subjects: 137
Study 33060437 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG+lactulose
Number of subjects: 60
Study 33060437 — intervention group
Group type: COMPARATOR
Intervention: SMT (lactulose)
Number of subjects: 60
Study 34745918 — intervention group
Group type: EXPERIMENTAL
Intervention: Squill oil
Number of subjects: 60
Study 34745918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 32878603 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Weissella cibaria CMU)
Number of subjects: 92
Study 32878603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 616121608 — intervention group
Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation (PRP) with intravitreal Ranibizumab (RBZ) injections (study group, SG)
Number of subjects: 50
Study 616121608 — intervention group
Group type: COMPARATOR
Intervention: Panretinal photocoagulation (PRP) alone (control group, CG)
Number of subjects: 50
Study 35739594 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Flipped Learning (VFL) using recorded online lectures and post-lecture virtual discussions
Number of subjects: 32
Study 35739594 — intervention group
Group type: COMPARATOR
Intervention: Virtual Traditional Learning (VTL) using live video lectures
Number of subjects: 32
Study 36372680 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (1 ml)
Number of subjects: 90
Study 36372680 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (1 ml)
Number of subjects: 90
Study 36372680 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate (control group)
Number of subjects: 90
Study 34292510 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 2604
Study 34292510 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2604
Study 32747213 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine
Number of subjects: 2000
Study 32747213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000
Study 35093141 — intervention group
Group type: EXPERIMENTAL
Intervention: NEON Intervention (recorded mental health recovery narratives)
Number of subjects: 0
Study 32199799 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine balloon for 28 days
Number of subjects: 138
Study 32199799 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine balloon for 14 days
Number of subjects: 138
Study 32199799 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine balloon for 7 days
Number of subjects: 138
Study 33346141 — intervention group
Group type: EXPERIMENTAL
Intervention: Early combined immunosuppression (ECI) for 24 months
Number of subjects: 0
Study 33346141 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (CM)
Number of subjects: 0
Study 33974761 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadership knowledge gaps regarding the scope of preceptor challenges, particularly time commitments and the number of preceptors required
Number of subjects: 12
Study 33974761 — intervention group
Group type: EXPERIMENTAL
Intervention: Improving career advancement or promotion criteria to recognize teaching efforts
Number of subjects: 12
Study 33974761 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced physician well‐being from teaching
Number of subjects: 12
Study 33974761 — intervention group
Group type: EXPERIMENTAL
Intervention: Distributed leadership
Number of subjects: 12
Study 32615663 — intervention group
Group type: EXPERIMENTAL
Intervention: Saffron pill
Number of subjects: 43
Study 32615663 — intervention group
Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 43
Study 36066760 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban garden and peer nutritional counseling intervention
Number of subjects: 115
Study 33955685 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to primary systemic therapy
Number of subjects: 988
Study 33955685 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 988
Study 33955685 — intervention group
Group type: EXPERIMENTAL
Intervention: Good performance status (ECOG 0–1)
Number of subjects: 988
Study 33955685 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to first‐line therapy
Number of subjects: 988
Study 33955685 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial local irradiation
Number of subjects: 988
Study 33955685 — intervention group
Group type: EXPERIMENTAL
Intervention: Three or more lines of systemic therapy
Number of subjects: 988
Study 33955685 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiative irradiation
Number of subjects: 988
Study 34254205 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment
Number of subjects: 0
Study 34254205 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment
Number of subjects: 0
Study 36243386 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) 400 μg BID
Number of subjects: 85
Study 36243386 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone furoate (FF) 100 μg QD
Number of subjects: 85
Study 36243386 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone furoate (FF) 200 μg QD
Number of subjects: 85
Study 36243386 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone furoate (FF) 400 μg QD
Number of subjects: 85
Study 36243386 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) therapeutic range (800 μg/day)
Number of subjects: 85
Study 36243386 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) therapeutic range (1000 μg/day)
Number of subjects: 85
Study 36243386 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) >3-fold above therapeutic dose range (644 μg/day)
Number of subjects: 85
Study 33528905 — intervention group
Group type: EXPERIMENTAL
Intervention: SBWI+RES (Restorative Hatha yoga)
Number of subjects: 50
Study 33528905 — intervention group
Group type: EXPERIMENTAL
Intervention: SBWI+VIN (Vinyasa yoga)
Number of subjects: 50
Study 33528905 — intervention group
Group type: COMPARATOR
Intervention: SBWI (Standard Behavioral Weight-loss Intervention)
Number of subjects: 50
Study 33528905 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga session duration
Number of subjects: 50
Study 33928435 — intervention group
Group type: EXPERIMENTAL
Intervention: AECT in a supine position
Number of subjects: 18
Study 33928435 — intervention group
Group type: COMPARATOR
Intervention: Compression-only therapy (CT) in a supine position
Number of subjects: 18
Study 33928435 — intervention group
Group type: EXPERIMENTAL
Intervention: AECT in a seated position
Number of subjects: 18
Study 35351696 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised nutritional plan with cluster-specific meals for 6 days a week and a personalised behavioural change programme via electronic push notifications.
Number of subjects: 100
Study 35351696 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving meals following general dietary recommendations and generic health behaviour prompts.
Number of subjects: 100
Study 35351696 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised nutritional plan
Number of subjects: 100
Study 33108212 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Number of subjects: 0
Study 33108212 — intervention group
Group type: COMPARATOR
Intervention: FF/VI
Number of subjects: 0
Study 33108212 — intervention group
Group type: COMPARATOR
Intervention: UMEC/VI
Number of subjects: 0
Study 32265309 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled aztreonam
Number of subjects: 0
Study 34274784 — intervention group
Group type: EXPERIMENTAL
Intervention: Check-up at a public health clinic
Number of subjects: 0
Study 34274784 — intervention group
Group type: COMPARATOR
Intervention: Control (no check-up)
Number of subjects: 0
Study 32459322 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Intravenous Analgesia (PCIA)
Number of subjects: 248
Study 32459322 — intervention group
Group type: COMPARATOR
Intervention: Epidural Analgesia (EDA)
Number of subjects: 248
Study 35092371 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Monitoring Quality of Life (SMQOL) intervention
Number of subjects: 225
Study 35092371 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 225
Study 33753319 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ultrasound-guided Erector Spinae Plane Block (ESPB) with 30 mL of 0.375% ropivacaine on each side
Number of subjects: 55
Study 33753319 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (postoperative muscular infiltration with 30 mL of 0.75% ropivacaine)
Number of subjects: 55
Study 34664152 — intervention group
Group type: EXPERIMENTAL
Intervention: Deception about occupation
Number of subjects: 644
Study 34664152 — intervention group
Group type: EXPERIMENTAL
Intervention: Deception about attractiveness
Number of subjects: 644
Study 34664152 — intervention group
Group type: EXPERIMENTAL
Intervention: Deception about volunteerism
Number of subjects: 644
Study 32023574 — intervention group
Group type: EXPERIMENTAL
Intervention: Visually guided laser balloon ablation (VGLB)
Number of subjects: 50
Study 32023574 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (RF)
Number of subjects: 50
Study 32023574 — intervention group
Group type: EXPERIMENTAL
Intervention: Visually guided laser balloon ablation (VGLB) with negative APT
Number of subjects: 50
Study 32023574 — intervention group
Group type: EXPERIMENTAL
Intervention: Visually guided laser balloon ablation (VGLB) with positive APT
Number of subjects: 50
Study 32023574 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (RF) with positive APT
Number of subjects: 50
Study 32023574 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (RF) with negative APT
Number of subjects: 50
Study 85119806 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for Schistosoma haematobium infection
Number of subjects: 0
Study 85119806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35334844 — intervention group
Group type: EXPERIMENTAL
Intervention: Short web-based sugar-rich food screener (SRFS)
Number of subjects: 80
Study 35334844 — intervention group
Group type: COMPARATOR
Intervention: Validated web-based 7-day dietary record
Number of subjects: 80
Study 35334844 — intervention group
Group type: EXPERIMENTAL
Intervention: Both assessment tools (SRFS and 7-day dietary record)
Number of subjects: 80
Study 32912103 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic medication on most days
Number of subjects: 14155
Study 32912103 — intervention group
Group type: EXPERIMENTAL
Intervention: Interference with sleep
Number of subjects: 14155
Study 32912103 — intervention group
Group type: EXPERIMENTAL
Intervention: Interference with walking
Number of subjects: 14155